Stocks
Viridian Therapeutics, Inc.VRDN
NASDAQHealthcareBiotechnology$22.37
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing antibody therapeutics for autoimmune and inflammatory diseases, with a lead candidate targeting thyroid eye disease. Investors track the stock for its late-stage clinical data readouts and potential FDA approval pathway.
52W Range: $13.18-$34.29
Congressional Interest in Viridian Therapeutics, Inc. (VRDN)
No congressional trades have been disclosed for Viridian Therapeutics, Inc. (VRDN) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading VRDN?
No congressional trades found for this stock.